- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01636635
Effect of Age and Weight Loss on Inflammation and Iron Homeostasis (HEP)
November 12, 2015 updated by: Simin Meydani, Tufts University
Effect of Age and Weight Loss on Obesity-related Inflammation and Iron Homeostasis in Women
The purpose of this study is to evaluate the effect of aging and weight loss on iron status and immune response in obese women.
Iron deficiency and immune impairment are two of the numerous complications of obesity.
The central hypothesis is that obesity-induced inflammation causes lower iron status through decreased iron absorption and availability in young and older obese women.
Furthermore, the investigators hypothesize that this can be corrected with weight loss in both young and older obese women.
Study Overview
Detailed Description
Obese individuals have chronic inflammation, higher risk of iron deficiency, and impaired immune response.
These are conditions seen also with aging, but it is unknown to what extent they may be further impacted by obesity in the elderly.
With this study the investigators aim to establish the mechanism by which weight loss may reduce inflammation and enhance iron status in young and older obese adults through the peptide hormone hepcidin, which regulates iron homeostasis.
The investigators also aim to identify a possible link between iron homeostasis and immune response through hepcidin, which has been implicated in T cell mediated immunity.
The investigators hypothesize that obesity-induced inflammation causes dysregulation of hepcidin expression leading to lower iron status through decreased iron absorption and availability in young and older adults.
Furthermore, the investigators hypothesize that hepcidin dysregulation, and thus iron status can be mitigated with weight loss in both young and older obese adults.
This hypothesis will be tested in obese young and older women undergoing weight loss through calorie restriction.
Change in iron status, inflammation, and hepcidin will be determined before and after weight loss.
Further, the impact of inflammatory environment of obesity on peripheral blood mononuclear cell hepcidin, ferroportin, intracellular iron, and T cell function in young and older adults will be determined.
This study will address two important public health problems, i.e. obesity and iron deficiency and will be an important step toward the identification of strategies to enhance health of obese young and older adults.
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- JM USDA Human Nutrition Research Center on Aging
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Enrolling patients in the Weight and Wellness Center (WWC) at Tufts Medical Center, part of their Tufts Employees, low calorie diet (LCD) or pre-surgical low calorie diet (PS-LCD) program, or enrolling at WWC as individual patients.
- BMI in the range of 30 to 55 kg/m2.
- Either ages 18-45 or >60.
Exclusion Criteria:
- Pregnancy.
- Weight reduction greater than or equal to 3% in the past 3 months.
- Prior gastric restrictive surgery.
- Weight loss medications within the 4 weeks prior to screening.
- History of eating disorder.
- Renal disease (serum creatinine >2mg/dl).
- Hepatic disease, except for nonalcoholic steatohepatitis (NASH).
- Celiac disease, or any kind of intestinal malabsorption disorders.
- Gastrointestinal cancer.
- Hereditary hemochromatosis, or any blood disorders.
- Chronic infectious or inflammatory disease.
- Use of immunosuppressants.
- Severe iron deficiency anemia (hemoglobin<8 g/dl) or other conditions that would prevent them from discontinuing iron supplement use.
- Unwilling to discontinue iron supplement intake. The dietary plan recommended by the WWC will include daily intake of iron that meets the iron RDA for the subject's gender and age group, therefore discontinuing iron supplement will not be harmful for the participants. Intake of other supplements will not be an exclusion criteria, as long as it stays constant throughout the study period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Young (18-45 years)
Obese young women (18-45y) undergoing calorie restriction.
|
Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
|
|
Experimental: Older (>60 years)
Obese older women (>60y) undergoing calorie restriction.
|
Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in serum hepcidin
Time Frame: Baseline and 12-16 weeks
|
The investigators will determine the change in hepcidin at baseline and after 12-16 weeks of calorie restriction.
|
Baseline and 12-16 weeks
|
|
Change in inflammation (CRP, IL-6)
Time Frame: Baseline and 12-16 weeks
|
The investigators will determine the change in inflammation at baseline and after 12-16 weeks of calorie restriction.
|
Baseline and 12-16 weeks
|
|
Change in iron status
Time Frame: Baseline and 12-16 weeks
|
The investigators will determine the change in iron status at baseline and after 12-16 weeks of calorie restriction.
|
Baseline and 12-16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in PBMC intracellular iron content
Time Frame: Baseline and 12-16 weeks
|
Baseline and 12-16 weeks
|
|
|
Change in PBMC Hepcidin expression
Time Frame: Baseline and 12-16 weeks
|
Baseline and 12-16 weeks
|
|
|
Change in PBMC ferroportin expression
Time Frame: Baseline and 12-16 weeks
|
Baseline and 12-16 weeks
|
|
|
Change in PBMC subpopulations and proliferation
Time Frame: Baseline and 12-16 weeks
|
After stimulation with ConA, PHA and anti-CD3/CD28
|
Baseline and 12-16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Simin N Meydani, DVM, PhD, Tufts University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Primary Completion (Actual)
November 1, 2013
Study Completion (Actual)
November 1, 2013
Study Registration Dates
First Submitted
January 26, 2012
First Submitted That Met QC Criteria
July 5, 2012
First Posted (Estimate)
July 10, 2012
Study Record Updates
Last Update Posted (Estimate)
November 16, 2015
Last Update Submitted That Met QC Criteria
November 12, 2015
Last Verified
November 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2765
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
Clinical Trials on Calorie Restriction
-
University of South CarolinaCompleted
-
St. Louis UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of CologneFresenius KabiCompletedAcute Renal FailureGermany
-
University of AarhusUniversity of Southern Denmark; University GhentCompletedOverweight and ObesityDenmark
-
SINEM BAYRAMCompletedObesity and Metabolic SyndromeTurkey
-
University of PernambucoUniversidade Federal de PernambucoEnrolling by invitationSarcopenia | Cardiac Disease | Metabolic Disease | Abdominal Obesity | Cardiometabolic SyndromeBrazil
-
Washington University School of MedicineCompleted
-
University of California, San FranciscoNational Institutes of Health (NIH)CompletedModerately Overweight IndividualsUnited States
-
Chin HsuCompleted